The company is best known for producing HurriCaine, a topical Benzocaine-based anesthetic gel used by dentists and introduced by the company more than 40 years ago. It was the first of its kind then and remains a sought after product in the market place.

“This is the perfect time to us to relocate,” said Beutlich CEO Erlene Thomas. “The move will be carried out in a manner that ensures our operations will not be interrupted and our loyal customers will not be affected.”

Beutlich Pharmaceuticals has been offering healthcare professionals unique solutions for pain management and preventative care since 1954. The company focuses on the development and commercialization of over-the-counter solutions for pain management and patient care.

The new building in Bunnell will offer more opportunities for the growing product lines that Beutlich offers and has created over the years. It will also allow them to take advantage of Flagler’s strong talent pool and cost-effective environment. The company is looking to fill positions in facility management, regulatory compliance, accounts receivable, marketing, shipping and production.